Overview: Total Complement CH50 TestIntroduction: The Total Complement CH50 Test measures total complement activity to diagnose immune disorders, causing frequent infections or autoimmune issues. Following 2023 ACR guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected immune deficiencies or autoimmune conditions.
Other Names: CH50 Assay, Complement Activity Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Complement testing began in the 1960s with immune disorder research. CH50 assays emerged in the 1970s, and by the 2000s, automated immunoassays improved diagnostic accuracy.
Purpose: Diagnoses immune disorders like systemic lupus erythematosus or complement deficiencies, guides treatment, and monitors complement activity in patients with frequent infections or autoimmune symptoms.
Test Parameters: 1. Complement Total CH50
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like recurrent infections or joint pain, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document recurrent infections, joint pain, or family history of autoimmune diseases. Include current medications, especially steroids or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure total complement activity. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Improper storage or hemolysis can degrade samples. Immunosuppressants may suppress complement levels, causing false negatives.
Clinical Significance: Low CH50 levels indicate complement deficiency or autoimmune activity, prompting treatment. Normal levels may require specific complement component testing.
Specialist Consultation: Consult a rheumatologist or immunologist for result interpretation. An infectious disease specialist referral is advised for recurrent infections.
Additional Supporting Tests: C3/C4 complement tests, ANA test, or immune function panel to confirm immune disorders.
Test Limitations: False negatives may occur with early disease or immunosuppression. Results require clinical correlation.
References: ACR Complement Guidelines, 2023; Arthritis and Rheumatology, Tsokos GC, 2022.
